The proportion of patients with schizophrenia considered as being non-compliant with antipsychotic medications ranges from 20% to 89%. Non-compliance has been associated with increase relapse rates, more frequent and longer hospitalizations. Costs of schizophrenia in the U.S. vary from $32 to $65 billion, but contradictory results have been reported for the costs of non-compliance among these patients. The objective was to estimate the costs of non-compliance with antipsychotic medications among patients with schizophrenia. METHODS: A literature review of studies published in the last decade was conducted. We utilized PubMed, Cochrane, EMBASE and CINADHL databases. The key terms included: (first: adherence, non-adherence, compliance, non-compliance), AND (second: schizophrenia, antipsychotics, atypical and typical antipsychotics, neuroleptics) AND (third: resource utilization, resource use, costs, economics, hospitalizations). Studies with data on costs of non-compliance or compliance were included. Two independent researchers reviewed the titles and abstracts and any differences were agreed by consensus. Costs were transformed in 2007 US dollars using the medical care price index. RESULTS: Of 43 studies, six fulfilled the inclusion criteria, including five retrospective cohort studies that used Medicaid paid claims, and a cross-sectional study that used the UK Psychiatric Morbidity Survey. Most studies had <3 years of follow-up. A total of 52,512 participants were studied. The percentage of non-compliant patients ranged from 11% to 31%. A study found that users of atypical antipsychotics (72%) have higher compliance than users of typical antipsychotics (56%). Non-compliant patients spent, on average, ten more days in the hospital, and have 22% more rehospitalizations than compliant patients. Costs of care for non-compliant patients were on average $3,104 higher than for compliant patients. CONCLUSION: Patients non-compliant with antipsychotics had more and longer hospitalizations, and higher total costs than compliant patients. Non-compliance with antipsychotics has significant clinical and economic implications for patients with schizophrenia.
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Ganapathy V 1 , McCombs JS 2 , Stafkey-Mailey D 1 , Kim E 3 , Pikalov A 4 1 University of Southern California School of Pharmacy, Los Angeles, CA, USA, 2 University of Southern California, Los Angeles, CA, USA, 3 Bristol-Myers Squibb, Plainsboro, NJ, USA, 4 Otsuka America Pharmaceuticals, Rockville, MD, USA OBJECTIVE: To compare time to all-cause discontinuation (TTAD) across alternative antipsychotics in the treatment of bipolar disorder (BD). METHODS: Data from a commercial health plan from July 1, 2003 to June 30, 2006 were used to identify non-institutionalized patients with bipolar disorder (ICD-9 296.4-296.8) but no history of schizophrenia (ICD-9 295.xx). Patients initiating treatment using a typical antipsychotic (TAP), atypical antipsychotic (AAP: aripiprazole, olanzapine, quetiapine, risperidone or ziprasidone), mood stabilizer or antidepressant were included. Episodes were divided into three categories: restarting treatment after a break in drug therapy >15 days with the drug used in the previous episode, switching therapy with or without a break in treatment, and augmentation therapy. First observed episodes were excluded from the analysis due to uncertainty concerning the patient's prior treatment history. A total of 106,447 episodes were included in the analyses using ordinary least squares (OLS) regression models of TTAD adjusting for age, gender, geographic region, drug use history, prior medical care use, bipolar disorder diagnosis and co-morbid medical conditions. RESULTS: Augmentation constituted over half of all treatment episodes (55.3%) and only 20% of all episodes included an antipsychotic. Patients initiating augmentation episodes achieved significantly longer TTAD initial therapy than patients initiating restart (+80 days, p < 0.0001) or switching episodes (+13 days, p < 0.0001). Moreover, these estimated differences increased significantly when TTAD was measured over all BD-related therapies (+155 days and +284 respectively). OLS results comparing initial therapies favored quetiapine, ziprasidone and aripiprazole relative to TAP in restart (+15 to +36 days), switching (+18 to +25 days) and augmentation episodes (+28 to +48 days)(p < 0.05 for 7 of 9 estimates). CON-CLUSION: In a commercially-insured population, patients with bipolar disorders initiating therapy using ziprasidone, aripiprazole or quetiapine have longer TTAD that TAP patients. Patients initiating augmentation therapy have much longer TTAD than other patients, especially when measured across all psychotropic medications.
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